Skip to main content
AAPS Open

Table 1 Immunogenicity sample collection schedule

From: Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

Cycle 1 (Predose)a

Cycle 2

Cycle 3

Cycle 4

Cycle 5

Cycle 6

Cycle 7

EOT

Patients with relapsed or refractory ALL who received single-agent InOb

x

  

x

   

x

x

x

x

x

x

x

 

x

Patients with relapsed or refractory NHL who received single-agent InOc

x

x

x

x

x

 

x

x

x

x

x

x

x

 

x

x

x

 

x

    

x

Patients with relapsed or refractory NHL who received InO plus rituximabc

 

x

x

x

x

 

x

x

 

x

x

x

x

 

x

x

x

       

x

  

x

   

x

x

x

x

x

x

x

 

x

Patients with relapsed or refractory NHL who received InO plus rituximab plus chemotherapyc

x

  

x

   

x

  1. Samples taken predose for respective treatment cycles
  2. ALL acute lymphoblastic leukemia, ECL electrochemiluminescence, ELISA enzyme-linked immunosorbent assay, EOT end of treatment, InO inotuzumab ozogamicin, NHL non-Hodgkin lymphoma
  3. aBefore first InO treatment. May have been omitted if sample taken at screening
  4. bECL assay
  5. cELISA
Back to article page